ESR2 and breast carcinoma: We used the SUM159 cell line, which expresses low levels of ERβ variants, since both ERβ2 and ERβ5 have been shown to correlate to clinical outcome of breast cancer [34–36], we chose to stably express the ERβ2 and ERβ5 variants in order to study changes in gene regulation.